PuREC
Tokyo, Japan· Est.
PuREC develops purified mesenchymal stem cell therapies for bone regeneration using its proprietary Rapidly-Expanding Cell (REC) platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $5.8M
AI Company Overview
PuREC develops purified mesenchymal stem cell therapies for bone regeneration using its proprietary Rapidly-Expanding Cell (REC) platform.
CardiovascularMusculoskeletal
Technology Platform
Rapidly-Expanding Cell (REC) platform for clonal isolation and expansion of highly purified mesenchymal stem cells (MSCs) using specific cell surface markers (LNGFR+THY-1+VCAM-1hi+).
Opportunities
Large addressable markets for bone disorders ($2.5B for HPP, $11B for spinal stenosis, $11B for joint diseases) and potential expansion into other mesenchymal lineage indications using the REC platform.
Risk Factors
Early clinical stage with unproven efficacy, cell therapy manufacturing and scalability challenges, regulatory hurdles for regenerative medicine products, and dependence on academic partnerships for clinical development.
Competitive Landscape
Competes with other MSC therapy developers and bone regeneration companies; differentiation through highly purified REC-MSCs with rapid expansion capabilities and specific targeting of bone disorders.